Back to top
more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$242.30 USD

242.30
1,213,436

+1.00 (0.41%)

Updated Apr 9, 2026 11:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (156 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kinjel Shah headshot

Should You Buy, Sell or Hold JNJ Stock Ahead of Q1 Earnings?

by Kinjel Shah

JNJ approaches Q1 results with strong drug growth and MedTech momentum. However, rising biosimilar competition and pricing pressures cloud the outlook.

Zacks Equity Research

Gear Up for Johnson & Johnson (JNJ) Q1 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top-and-bottom-line estimates for Johnson & Johnson (JNJ), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.

Zacks Equity Research

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Equity Research

Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to Know

by Zacks Equity Research

Johnson & Johnson (JNJ) closed at $241.3 in the latest trading session, marking a +1.21% move from the prior day.

Kinjel Shah headshot

How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results

by Kinjel Shah

Pfizer's oncology unit displays mixed Q1 trends as key drugs and biosimilars offset Ibrance declines ahead of earnings on May 5

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Sundeep Ganoria headshot

How Will Skyrizi and Rinvoq Shape AbbVie's Q1 Immunology Sales?

by Sundeep Ganoria

ABBV heads into Q1 earnings with Skyrizi and Rinvoq in focus as Humira declines, while growth from new indications and market share gains is under watch.

Zacks Equity Research

Bayer Advances AB-1002 Study, Highlights Pharma Growth Strategy

by Zacks Equity Research

Bayer advances AB-1002 after AskBio completes mid-stage study enrollment, as its Pharma strategy and pipeline milestones drive long-term growth outlook.

Kinjel Shah headshot

JNJ Q1 MedTech Preview: Key Drivers and China Headwinds to Watch

by Kinjel Shah

JNJ's MedTech unit rides cardiovascular strength and new product adoption, but China headwinds loom ahead of its Q1 earnings release.

Zacks Equity Research

Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.